Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (9): 815-820.DOI: 10.3969/j.issn.1673-8640.2022.09.003
Previous Articles Next Articles
WANG Xiaoye1, DONG Guoyou1, LIU Zhiying2()
Received:
2020-08-07
Revised:
2021-09-03
Online:
2022-09-30
Published:
2022-10-25
Contact:
LIU Zhiying
CLC Number:
WANG Xiaoye, DONG Guoyou, LIU Zhiying. Relations of ZEB2 and E-Cad expressions in breast cancer tissues with prognosis[J]. Laboratory Medicine, 2022, 37(9): 815-820.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.09.003
组织 | ZEB2 | E-Cad | |||
---|---|---|---|---|---|
免疫组化评分/分 | 阳性/ [例(%)] | 免疫组化评分/分 | 阳性/ [例(%)] | ||
癌旁组织 | 0.85±0.42 | 8(10.00) | 6.25±1.54 | 76(95.00) | |
癌组织 | 6.74±1.91 | 68(85.00) | 5.21±0.33 | 10(12.50) | |
统计值 | 26.938 | 90.226 | 5.906 | 109.516 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
组织 | ZEB2 | E-Cad | |||
---|---|---|---|---|---|
免疫组化评分/分 | 阳性/ [例(%)] | 免疫组化评分/分 | 阳性/ [例(%)] | ||
癌旁组织 | 0.85±0.42 | 8(10.00) | 6.25±1.54 | 76(95.00) | |
癌组织 | 6.74±1.91 | 68(85.00) | 5.21±0.33 | 10(12.50) | |
统计值 | 26.938 | 90.226 | 5.906 | 109.516 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
临床病理参数 | 例数 | ZEB2阳性/ [例(%)] | E-Cad阳性/ [例(%)] | 临床病理参数 | 例数 | ZEB2阳性/ [例(%)] | E-Cad阳性/ [例(%)] |
---|---|---|---|---|---|---|---|
年龄 | PR表达 | ||||||
<50岁 | 40 | 31(77.50) | 3(7.50) | 阳性 | 55 | 45(81.82) | 2(3.64) |
≥50岁 | 40 | 37(92.50) | 7(17.50) | 阴性 | 25 | 23(92.00) | 8(32.00) |
χ2值 | 3.529 | 1.829 | χ2值 | 1.398 | 12.642 | ||
P值 | 0.060 | 0.176 | P值 | 0.237 | <0.001 | ||
肿瘤直径 | HER-2表达 | ||||||
<1.5 cm | 37 | 28(75.68) | 3(8.11) | 阳性 | 43 | 33(81.13) | 1(2.33) |
≥1.5 cm | 43 | 40(93.02) | 7(16.27) | 阴性 | 37 | 35(92.59) | 9(24.32) |
χ2值 | 4.694 | 1.214 | χ2值 | 4.970 | 8.800 | ||
P值 | 0.030 | 0.271 | P值 | 0.026 | 0.003 | ||
淋巴结转移 | 0 | 分子分型 | |||||
有 | 34 | 24(70.59) | 8(23.53) | Luminal A型 | 36 | 30(18.87) | 6(16.67) |
无 | 46 | 44(95.65) | 2(4.35) | Luminal B型 | 11 | 10(18.87) | 1(9.09) |
χ2值 | 9.632 | 6.577 | HER-2过表达型 | 22 | 18(18.87) | 2(9.09) | |
P值 | 0.002 | 0.01 | 基底样型 | 11 | 10(18.87) | 1(9.09) | |
远隔转移 | χ2值 | 0.856 | 1.039 | ||||
有 | 37 | 30(81.08) | 3(23.53) | P值 | 0.836 | 0.792 | |
无 | 43 | 38(88.37) | 7(4.35) | 病理类型 | |||
χ2值 | 0.829 | 1.214 | 浸润性导管癌 | 63 | 54(85.71) | 8(12.70) | |
P值 | 0.363 | 0.271 | 其他类型 | 17 | 14(82.35) | 2(11.76) | |
TNM分期 | χ2值 | 0.119 | 0.011 | ||||
Ⅰ~Ⅱ期 | 53 | 42(41.03) | 3(5.66) | P值 | 0.731 | 0.918 | |
Ⅲ~Ⅳ期 | 27 | 26(14.63) | 7(25.93) | 组织学分级 | |||
χ2值 | 4.079 | 6.716 | Ⅰ~Ⅱ级 | 62 | 53(85.49) | 6(9.68) | |
P值 | 0.043 | 0.001 | Ⅲ级 | 18 | 15(83.33) | 4(22.22) | |
ER表达 | χ2值 | 0.051 | 2.008 | ||||
阳性 | 53 | 43(81.13) | 2(3.77) | P值 | 0.822 | 0.157 | |
阴性 | 27 | 25(92.59) | 8(29.63) | ||||
χ2值 | 1.843 | 10.933 | |||||
P值 | 0.175 | 0.001 |
临床病理参数 | 例数 | ZEB2阳性/ [例(%)] | E-Cad阳性/ [例(%)] | 临床病理参数 | 例数 | ZEB2阳性/ [例(%)] | E-Cad阳性/ [例(%)] |
---|---|---|---|---|---|---|---|
年龄 | PR表达 | ||||||
<50岁 | 40 | 31(77.50) | 3(7.50) | 阳性 | 55 | 45(81.82) | 2(3.64) |
≥50岁 | 40 | 37(92.50) | 7(17.50) | 阴性 | 25 | 23(92.00) | 8(32.00) |
χ2值 | 3.529 | 1.829 | χ2值 | 1.398 | 12.642 | ||
P值 | 0.060 | 0.176 | P值 | 0.237 | <0.001 | ||
肿瘤直径 | HER-2表达 | ||||||
<1.5 cm | 37 | 28(75.68) | 3(8.11) | 阳性 | 43 | 33(81.13) | 1(2.33) |
≥1.5 cm | 43 | 40(93.02) | 7(16.27) | 阴性 | 37 | 35(92.59) | 9(24.32) |
χ2值 | 4.694 | 1.214 | χ2值 | 4.970 | 8.800 | ||
P值 | 0.030 | 0.271 | P值 | 0.026 | 0.003 | ||
淋巴结转移 | 0 | 分子分型 | |||||
有 | 34 | 24(70.59) | 8(23.53) | Luminal A型 | 36 | 30(18.87) | 6(16.67) |
无 | 46 | 44(95.65) | 2(4.35) | Luminal B型 | 11 | 10(18.87) | 1(9.09) |
χ2值 | 9.632 | 6.577 | HER-2过表达型 | 22 | 18(18.87) | 2(9.09) | |
P值 | 0.002 | 0.01 | 基底样型 | 11 | 10(18.87) | 1(9.09) | |
远隔转移 | χ2值 | 0.856 | 1.039 | ||||
有 | 37 | 30(81.08) | 3(23.53) | P值 | 0.836 | 0.792 | |
无 | 43 | 38(88.37) | 7(4.35) | 病理类型 | |||
χ2值 | 0.829 | 1.214 | 浸润性导管癌 | 63 | 54(85.71) | 8(12.70) | |
P值 | 0.363 | 0.271 | 其他类型 | 17 | 14(82.35) | 2(11.76) | |
TNM分期 | χ2值 | 0.119 | 0.011 | ||||
Ⅰ~Ⅱ期 | 53 | 42(41.03) | 3(5.66) | P值 | 0.731 | 0.918 | |
Ⅲ~Ⅳ期 | 27 | 26(14.63) | 7(25.93) | 组织学分级 | |||
χ2值 | 4.079 | 6.716 | Ⅰ~Ⅱ级 | 62 | 53(85.49) | 6(9.68) | |
P值 | 0.043 | 0.001 | Ⅲ级 | 18 | 15(83.33) | 4(22.22) | |
ER表达 | χ2值 | 0.051 | 2.008 | ||||
阳性 | 53 | 43(81.13) | 2(3.77) | P值 | 0.822 | 0.157 | |
阴性 | 27 | 25(92.59) | 8(29.63) | ||||
χ2值 | 1.843 | 10.933 | |||||
P值 | 0.175 | 0.001 |
指标 | β值 | 标准误 | Wald值 | P值 | HR值(95%CI) |
---|---|---|---|---|---|
肿瘤直径 | 4.03 | 3.65 | 2.91 | 0.68 | 0.82(0.77~2.75) |
淋巴结转移 | 2.34 | 1.08 | 4.26 | 0.01 | 3.47(2.48~5.67) |
ER | 3.78 | 3.33 | 2.84 | 0.76 | 0.77(0.72~3.35) |
PR | 4.05 | 3.15 | 2.67 | 0.85 | 0.81(0.74~4.24) |
HER-2 | 3.86 | 3.52 | 2.83 | 0.88 | 0.85(0.69~2.68) |
TNM分期 | 1.65 | 0.93 | 2.77 | 0.03 | 6.49(1.17~8.67) |
ZEB2 | 3.58 | 1.98 | 2.74 | 0.01 | 2.35(2.00~5.64) |
E-Cad | -0.64 | 0.44 | 0.001 | 0.01 | 0.15(0.08~0.78) |
指标 | β值 | 标准误 | Wald值 | P值 | HR值(95%CI) |
---|---|---|---|---|---|
肿瘤直径 | 4.03 | 3.65 | 2.91 | 0.68 | 0.82(0.77~2.75) |
淋巴结转移 | 2.34 | 1.08 | 4.26 | 0.01 | 3.47(2.48~5.67) |
ER | 3.78 | 3.33 | 2.84 | 0.76 | 0.77(0.72~3.35) |
PR | 4.05 | 3.15 | 2.67 | 0.85 | 0.81(0.74~4.24) |
HER-2 | 3.86 | 3.52 | 2.83 | 0.88 | 0.85(0.69~2.68) |
TNM分期 | 1.65 | 0.93 | 2.77 | 0.03 | 6.49(1.17~8.67) |
ZEB2 | 3.58 | 1.98 | 2.74 | 0.01 | 2.35(2.00~5.64) |
E-Cad | -0.64 | 0.44 | 0.001 | 0.01 | 0.15(0.08~0.78) |
[1] | 郑莹. 中国乳腺癌患者生活方式指南[J]. 浙江医学, 2017, 39(4):239-242. |
[2] |
ZHAO C L, SINGH K, BRODSKY A S, et al. Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer[J]. BMC Cancer, 2019, 19(1):1036.
DOI PMID |
[3] |
NEELAKANTAN D, ZHOU H, OLIPHANT M U J, et al. EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells[J]. Nat Commun, 2017, 8:15773.
DOI PMID |
[4] | MA X, YAN W, DAI Z, et al. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway[J]. Drug Des Devel Ther, 2016, 10:1419-1441. |
[5] |
ZHANG Z, YANG C, GAO W, et al. FOXA2 attenuates the epithelial to mesenchymal transition by regulating the transcription of E-cadherin and ZEB2 in human breast cancer[J]. Cancer Lett, 2015, 361(2):240-250.
DOI PMID |
[6] | 孙振, 周海红, 郭红云, 等. CARD9蛋白在乳腺癌组织中的表达及其临床意义[J]. 肿瘤, 2017, 37(3):245-254. |
[7] |
GOLDHIRSCH A, WOOD W C, COATES A S, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol, 2011, 22(8):1736-1747.
DOI PMID |
[8] |
PRECA B T, BAJDAK K, MOCK K, et al. A novel ZEB1/HAS2 positive feedback loop promotes EMT in breast cancer[J]. Oncotarget, 2017, 8(7):11530-11543.
DOI URL |
[9] | 李艳娇, 张本斯, 李庄, 等. EphA2在乳腺癌中的表达及其与上皮间质转化的关系[J]. 中国临床解剖学杂志, 2018, 36(3):294-298. |
[10] |
DANG D K, MAKENA M R, LLONGUERAS J P, et al. A Ca2+-ATPase regulates E-cadherin biogenesis and epithelial-mesenchymal transition in breast cancer cells[J]. Mol Cancer Res, 2019, 17(8):1735-1747.
DOI URL |
[11] | 邹颖, 邝紫桥, 陈欣欣, 等. Sam68基因过表达可促进乳腺癌MCF-7细胞发生上皮-间质转化[J]. 肿瘤, 2017, 37(1):12-18. |
[12] |
DI GENNARO A, DAMIANO V, BRISOTTO G, et al. A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness[J]. Cell Death Differ, 2018, 25(12):2165-2180.
DOI PMID |
[13] |
XAVIER P L P, CORDEIRO Y G, ROCHETTI A L, et al. ZEB1 and ZEB2 transcription factors are potential therapeutic targets of canine mammary cancer cells[J]. Vet Comp Oncol, 2018, 16(4):596-605.
DOI PMID |
[14] |
ZHOU X, MEN X, ZHAO R, et al. MiR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer[J]. Cancer Gene Ther, 2018, 25(3-4):68-76.
DOI PMID |
[15] | 罗庆丰, 修穆群, 高文, 等. ZEB2蛋白表达和E-caderin蛋白在鼻咽癌转移中的临床意义[J]. 实用癌症杂志, 2019, 34(5):704-706. |
[1] | WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35 [J]. Laboratory Medicine, 2023, 38(9): 812-817. |
[2] | WANG Yangshuyi, YE WEI, LIN Zhihao, HUANG Yuenuo, FANG Tao, DONG Xiaoting. Construction and validation of a model for pyroptosis-related features in lung adenocarcinoma [J]. Laboratory Medicine, 2023, 38(9): 833-841. |
[3] | ZHANG Han, LI Jun, LIU Xiaojiang, GUAN Yixiang. Role of serum albumin,interleukin-6 and ferritin combined determination in evaluating the functional prognosis of patients with spontaneous intracerebral hemorrhage [J]. Laboratory Medicine, 2023, 38(8): 713-718. |
[4] | ZHANG Na, NIU Weihua, SUN Yuanyuan, JIA Mei. CMV and EBV co-infection affecting patient prognosis after hematopoietic stem cell transplantation [J]. Laboratory Medicine, 2023, 38(8): 760-765. |
[5] | GUO Jie, LI Haixia, LI Xiaoyun. Correlation of preoperative RPR in peripheral blood with the prognosis of endometrial carcinoma patients [J]. Laboratory Medicine, 2023, 38(7): 675-679. |
[6] | WANG Tengfei, CHEN Shan, AN Hebing, ZHOU Lei. Expressions and roles of lncRNA CRNDE and miR-384 in peripheral blood of patients with acute leukemia [J]. Laboratory Medicine, 2023, 38(7): 686-691. |
[7] | YIN Ya, PAN Yuan, ZHOU Hongwei, SHEN Wei. Application progress of BNP and NT-proBNP in neonates [J]. Laboratory Medicine, 2023, 38(6): 518-523. |
[8] | CHEN Chen, DUAN Qi, LU Jiatuan, ZHAI Xiaojian, WANG Zheng, ZHANG Hao, GUO Man. Expressions of ASH2L and HOXA2 in triple-negative breast cancer patients and their relationship with lymph node metastasis [J]. Laboratory Medicine, 2023, 38(6): 574-578. |
[9] | ZHAO Jing, WANG Pei, LU Dandan, QI Dandan, LI Xuan. Expression levels of serum miR-4443 and TRAF4 in patients with hemorrhagic stroke [J]. Laboratory Medicine, 2023, 38(5): 413-418. |
[10] | ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Changes of serum HAS2 and CD44 levels in breast cancer patients and their clinical significance [J]. Laboratory Medicine, 2023, 38(5): 424-429. |
[11] | SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351. |
[12] | LIU Junshan, GUO Mingfa, SUN Jia, SHI Lihuan, LIU Wei, DUAN Yongtao. Significance of minimal residual disease dynamic monitoring in the prognosis of acute B-lymphoblastic leukemia children with positive and negative ETV6/RUNX1 fusion genes [J]. Laboratory Medicine, 2023, 38(3): 209-214. |
[13] | LI Mu, GONG Dongliang, XU Liming, PENG Rong. Relationship of XPC rs2228000 polymorphisms and breast cancer [J]. Laboratory Medicine, 2023, 38(3): 235-239. |
[14] | CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256. |
[15] | LIU Chong, ZHANG Jing, LI Sheng, ZHAO Qi. Expressions and correlation of miR-335 and Fra-1 in breast cancer [J]. Laboratory Medicine, 2023, 38(2): 143-147. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||